spironolactone has been researched along with Inflammation in 55 studies
Spironolactone: A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827)
spironolactone : A steroid lactone that is 17alpha-pregn-4-ene-21,17-carbolactone substituted by an oxo group at position 3 and an alpha-acetylsulfanyl group at position 7.
Inflammation: A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The studies were double-blind, randomised, placebo-controlled studies in 46 type 1 and 23 type 2 diabetic patients with micro- or macroalbuminuria treated with angiotensin-converting enzyme inhibitor (ACE inhibitor) or angiotensin receptor blocker (ARB), and randomised to additional treatment with spironolactone 25 mg and placebo daily for 60 days." | 9.17 | Levels of NT-proBNP, markers of low-grade inflammation, and endothelial dysfunction during spironolactone treatment in patients with diabetic kidney disease. ( Nielsen, SE; Parving, HH; Persson, F; Rossing, K; Rossing, P; Schalkwijk, CG; Schjoedt, KJ; Stehouwer, CD, 2013) |
| " Studies comparing the effect of spironolactone to placebo in patients with hypertension and DM were included." | 9.12 | A systematic review and meta-analysis of effects of spironolactone on blood pressure, glucose, lipids, renal function, fibrosis and inflammation in patients with hypertension and diabetes. ( Abudoyreyimu, R; Heizati, M; Li, N; Lin, M; Nurula, M; Wang, L; Wang, Z; Wu, Z; Yang, Z, 2021) |
| " The Eplerenone Neurohormonal Efficacy and Survival Study (EPHESUS) with eplerenone in patients who were post-myocardial infarction underscores the additive benefit of such a strategy in post-infarction patients that typify an at-risk population for recurrent cardiovascular events." | 8.82 | Eplerenone: will it have a role in the treatment of acute coronary syndromes? ( Meier, DJ; Pitt, B; Rajagopalan, S, 2004) |
| " The aim of this study was to investigate the effect of LDS on dyslipidemia and hepatic inflammation in rats with letrozole (LET)-induced PCOS and to assess the possible involvement of PCSK9 in these effects." | 8.31 | Low-dose spironolactone combats dyslipidemia and hepatic inflammation by modulating PCSK9 in rat model of polycystic ovarian syndrome. ( Agbana, RD; Ajadi, IO; Areloegbe, SE; Areola, ED; Atuma, CL; Fafure, AA; Olaniyi, KS; Olatunji, LA; Sabinari, IW; Shah, MZUH, 2023) |
| "Altogether, the present study suggests that low-dose spironolactone confers protection against adipose dysfunction in experimental PCOS animals by attenuating inflammation, oxidative stress and cellular apoptosis." | 8.12 | Low-dose spironolactone ameliorates adipose tissue inflammation and apoptosis in letrozole-induced PCOS rat model. ( Areloegbe, SE; Olaniyi, KS; Oyeleke, MB; Peter, MU, 2022) |
| " This study's aim was to determine whether chronic spironolactone treatment prevents formation of local electrical activation delays in the cardiomyopathic ventricle by attenuating inflammatory pathways and myocardial fibrosis." | 7.79 | Spironolactone improves the arrhythmogenic substrate in heart failure by preventing ventricular electrical activation delays associated with myocardial interstitial fibrosis and inflammation. ( Esposito, CT; Jeyaraj, D; Lu, Y; Stambler, BS; Varahan, S, 2013) |
| " However, eplerenone inhibited the development of renal fibrosis, inflammation (macrophage and monocyte infiltration), interstitial cell proliferation, and activation of interstitial cells (α-SMA expression)." | 7.79 | Eplerenone-mediated aldosterone blockade prevents renal fibrosis by reducing renal inflammation, interstitial cell proliferation and oxidative stress. ( Chen, H; Liu, Y; Shao, Y; Sun, F; Yoshimura, A; Zhong, X, 2013) |
| " Using this pain model, the authors applied the MR antagonist eplerenone locally to the inflamed DRG." | 7.78 | Mineralocorticoid receptor blocker eplerenone reduces pain behaviors in vivo and decreases excitability in small-diameter sensory neurons from local inflamed dorsal root ganglia in vitro. ( Dong, F; Strong, JA; Xie, W; Zhang, JM, 2012) |
| "Persistent β-adrenergic receptor stimulation with isoproterenol is associated with cardiac hypertrophy as well as cardiac synthesis of angiotensin II." | 7.78 | Spironolactone prevents alterations associated with cardiac hypertrophy produced by isoproterenol in rats: involvement of serum- and glucocorticoid-regulated kinase type 1. ( Ballesteros, S; Cachofeiro, V; Davel, AP; de las Heras, N; Lahera, V; Martín-Fernández, B; Miana, M; Rossoni, LV; Valero-Muñoz, M; Vassallo, D, 2012) |
| "Recent evidence suggests that treatment with mineralocorticoid receptor antagonist suppressed local inflammation in vascular tissues or cardiomyocytes; therefore, we examined the effect of spironolactone on glucose and lipid metabolism in a mouse model with diet-induced diabetes and nonalcoholic fatty liver disease." | 7.76 | Spironolactone improves glucose and lipid metabolism by ameliorating hepatic steatosis and inflammation and suppressing enhanced gluconeogenesis induced by high-fat and high-fructose diet. ( Kenmochi, H; Koya, D; Miyashita, Y; Ojima, M; Sasahara, M; Sasaki, M; Sasaoka, T; Tsuneki, H; Wada, T, 2010) |
| "These results suggest that aldosterone may play a critical role in atherogenesis subsequent to oxidative stress in part independent of angiotensin II-mediated signaling, and that eplerenone could prevent atherosclerosis by attenuating oxidative stress and inflammation." | 7.73 | Eplerenone with valsartan effectively reduces atherosclerotic lesion by attenuation of oxidative stress and inflammation. ( Higaki, J; Horiuchi, M; Iwai, M; Mogi, M; Oshita, A; Suzuki, J; Yoshii, T, 2006) |
| "Hirsutism is a dermatological condition that refers to the excessive growth of hair in androgen-sensitive areas in women." | 5.62 | Pharmaceutical and Pharmacological Evaluation of the Effect of Nano-Formulated Spironolactone and Progesterone on Inflammation and Hormonal Levels for Managing Hirsutism Experimentally Induced in Rats. ( Amer, RI; Fayez, AM; Mohamed, RA; Yassin, GE, 2021) |
| " Longer duration or higher dosage of spironolactone seems to be more effective in improving cardiovascular system status in PD patients." | 5.46 | Aldosterone antagonist therapy and its relationship with inflammation, fibrosis, thrombosis, mineral-bone disorder and cardiovascular complications in peritoneal dialysis (PD) patients. ( Donderski, R; Grajewska, M; Manitius, J; Miśkowiec, I; Odrowąż-Sypniewska, G; Siódmiak, J; Stefańska, A; Stróżecki, P; Sulikowska, B, 2017) |
| "Spironolactone is an antifibrotic medication commonly used in heart failure to reduce mortality." | 5.38 | Spironolactone and colitis: increased mortality in rodents and in humans. ( Gillespie, BW; Govani, SM; Higgins, PD; Johnson, LA; Joyce, JC; Waljee, AK, 2012) |
| "Spironolactone treatment markedly suppressed osteopontin expression." | 5.35 | Spironolactone suppresses inflammation and prevents L-NAME-induced renal injury in rats. ( Hayashida, H; Hirakata, H; Iida, M; Ikeda, H; Masutani, K; Toyonaga, J; Tsuruya, K, 2009) |
| "The studies were double-blind, randomised, placebo-controlled studies in 46 type 1 and 23 type 2 diabetic patients with micro- or macroalbuminuria treated with angiotensin-converting enzyme inhibitor (ACE inhibitor) or angiotensin receptor blocker (ARB), and randomised to additional treatment with spironolactone 25 mg and placebo daily for 60 days." | 5.17 | Levels of NT-proBNP, markers of low-grade inflammation, and endothelial dysfunction during spironolactone treatment in patients with diabetic kidney disease. ( Nielsen, SE; Parving, HH; Persson, F; Rossing, K; Rossing, P; Schalkwijk, CG; Schjoedt, KJ; Stehouwer, CD, 2013) |
| " Studies comparing the effect of spironolactone to placebo in patients with hypertension and DM were included." | 5.12 | A systematic review and meta-analysis of effects of spironolactone on blood pressure, glucose, lipids, renal function, fibrosis and inflammation in patients with hypertension and diabetes. ( Abudoyreyimu, R; Heizati, M; Li, N; Lin, M; Nurula, M; Wang, L; Wang, Z; Wu, Z; Yang, Z, 2021) |
| "In RALES, low doses of the mineralocorticoid receptor (MR) antagonist spironolactone, added to standard of care for severe heart failure, improved survival by 30% and lowered hospitalization by 35%." | 5.11 | RALES, EPHESUS and redox. ( Funder, JW, 2005) |
| " The Eplerenone Neurohormonal Efficacy and Survival Study (EPHESUS) with eplerenone in patients who were post-myocardial infarction underscores the additive benefit of such a strategy in post-infarction patients that typify an at-risk population for recurrent cardiovascular events." | 4.82 | Eplerenone: will it have a role in the treatment of acute coronary syndromes? ( Meier, DJ; Pitt, B; Rajagopalan, S, 2004) |
| " The aim of this study was to investigate the effect of LDS on dyslipidemia and hepatic inflammation in rats with letrozole (LET)-induced PCOS and to assess the possible involvement of PCSK9 in these effects." | 4.31 | Low-dose spironolactone combats dyslipidemia and hepatic inflammation by modulating PCSK9 in rat model of polycystic ovarian syndrome. ( Agbana, RD; Ajadi, IO; Areloegbe, SE; Areola, ED; Atuma, CL; Fafure, AA; Olaniyi, KS; Olatunji, LA; Sabinari, IW; Shah, MZUH, 2023) |
| "Altogether, the present study suggests that low-dose spironolactone confers protection against adipose dysfunction in experimental PCOS animals by attenuating inflammation, oxidative stress and cellular apoptosis." | 4.12 | Low-dose spironolactone ameliorates adipose tissue inflammation and apoptosis in letrozole-induced PCOS rat model. ( Areloegbe, SE; Olaniyi, KS; Oyeleke, MB; Peter, MU, 2022) |
| "Bisphosphonate, tetracycline and spironolactone use has been shown to increase gastro-oesophageal inflammation, an accepted risk factor for cancer." | 3.85 | The effect of medications which cause inflammation of the gastro-oesophageal tract on cancer risk: a nested case-control study of routine Scottish data. ( Busby, J; Cardwell, CR; Iversen, L; Lee, AJ; Murchie, P; Murray, L; Spence, A; Watson, MC, 2017) |
| " The MR/GR agonist 6-α methylprednisolone, commonly injected for low back pain, reduced mechanical hypersensitivity when applied locally to the DRG but was less effective than fluticasone." | 3.80 | Blocking the mineralocorticoid receptor improves effectiveness of steroid treatment for low back pain in rats. ( Strong, JA; Xie, W; Ye, L; Zhang, JM, 2014) |
| " However, eplerenone inhibited the development of renal fibrosis, inflammation (macrophage and monocyte infiltration), interstitial cell proliferation, and activation of interstitial cells (α-SMA expression)." | 3.79 | Eplerenone-mediated aldosterone blockade prevents renal fibrosis by reducing renal inflammation, interstitial cell proliferation and oxidative stress. ( Chen, H; Liu, Y; Shao, Y; Sun, F; Yoshimura, A; Zhong, X, 2013) |
| " This study's aim was to determine whether chronic spironolactone treatment prevents formation of local electrical activation delays in the cardiomyopathic ventricle by attenuating inflammatory pathways and myocardial fibrosis." | 3.79 | Spironolactone improves the arrhythmogenic substrate in heart failure by preventing ventricular electrical activation delays associated with myocardial interstitial fibrosis and inflammation. ( Esposito, CT; Jeyaraj, D; Lu, Y; Stambler, BS; Varahan, S, 2013) |
| "Persistent β-adrenergic receptor stimulation with isoproterenol is associated with cardiac hypertrophy as well as cardiac synthesis of angiotensin II." | 3.78 | Spironolactone prevents alterations associated with cardiac hypertrophy produced by isoproterenol in rats: involvement of serum- and glucocorticoid-regulated kinase type 1. ( Ballesteros, S; Cachofeiro, V; Davel, AP; de las Heras, N; Lahera, V; Martín-Fernández, B; Miana, M; Rossoni, LV; Valero-Muñoz, M; Vassallo, D, 2012) |
| " Using this pain model, the authors applied the MR antagonist eplerenone locally to the inflamed DRG." | 3.78 | Mineralocorticoid receptor blocker eplerenone reduces pain behaviors in vivo and decreases excitability in small-diameter sensory neurons from local inflamed dorsal root ganglia in vitro. ( Dong, F; Strong, JA; Xie, W; Zhang, JM, 2012) |
| "Recent evidence suggests that treatment with mineralocorticoid receptor antagonist suppressed local inflammation in vascular tissues or cardiomyocytes; therefore, we examined the effect of spironolactone on glucose and lipid metabolism in a mouse model with diet-induced diabetes and nonalcoholic fatty liver disease." | 3.76 | Spironolactone improves glucose and lipid metabolism by ameliorating hepatic steatosis and inflammation and suppressing enhanced gluconeogenesis induced by high-fat and high-fructose diet. ( Kenmochi, H; Koya, D; Miyashita, Y; Ojima, M; Sasahara, M; Sasaki, M; Sasaoka, T; Tsuneki, H; Wada, T, 2010) |
| "These results suggest that aldosterone may play a critical role in atherogenesis subsequent to oxidative stress in part independent of angiotensin II-mediated signaling, and that eplerenone could prevent atherosclerosis by attenuating oxidative stress and inflammation." | 3.73 | Eplerenone with valsartan effectively reduces atherosclerotic lesion by attenuation of oxidative stress and inflammation. ( Higaki, J; Horiuchi, M; Iwai, M; Mogi, M; Oshita, A; Suzuki, J; Yoshii, T, 2006) |
| "Although insulin resistance is not part of the diagnostic criteria for PCOS, its importance in the pathogenesis of PCOS can not be denied." | 2.43 | Insulin resistance in polycystic ovarian disease. ( Bhatia, V, 2005) |
| "Other comorbidities included bronchial asthma, chronic sinusitis, ischemic heart disease, mild aortic stenosis, arterial hypertension, and degenerative thoracic spine disease." | 1.72 | Torasemide-induced Vascular Purpura in the Course of Eosinophilic Granulomatosis with Polyangiitis. ( Bergler-Czop, B; Frątczak, A; Miziołek, B; Polak, K, 2022) |
| "Hirsutism is a dermatological condition that refers to the excessive growth of hair in androgen-sensitive areas in women." | 1.62 | Pharmaceutical and Pharmacological Evaluation of the Effect of Nano-Formulated Spironolactone and Progesterone on Inflammation and Hormonal Levels for Managing Hirsutism Experimentally Induced in Rats. ( Amer, RI; Fayez, AM; Mohamed, RA; Yassin, GE, 2021) |
| " Longer duration or higher dosage of spironolactone seems to be more effective in improving cardiovascular system status in PD patients." | 1.46 | Aldosterone antagonist therapy and its relationship with inflammation, fibrosis, thrombosis, mineral-bone disorder and cardiovascular complications in peritoneal dialysis (PD) patients. ( Donderski, R; Grajewska, M; Manitius, J; Miśkowiec, I; Odrowąż-Sypniewska, G; Siódmiak, J; Stefańska, A; Stróżecki, P; Sulikowska, B, 2017) |
| " There was a marked decrease in nitric oxide (NO) bioavailability and antioxidant enzyme capacity." | 1.40 | Combination therapy with spironolactone and candesartan protects against streptozotocin-induced diabetic nephropathy in rats. ( El-Moselhy, MA; Hofni, A; Khalifa, MM; Taye, A, 2014) |
| "Canrenone is a derivative of spironolactone with lower antiandrogen activity." | 1.40 | Aldosterone receptor blockers spironolactone and canrenone: two multivalent drugs. ( Armanini, D; Bordin, L; Clari, G; Donà, G; Sabbadin, C, 2014) |
| "Aldosterone plays a crucial role in cardiovascular disease." | 1.39 | Endothelial mineralocorticoid receptor activation mediates endothelial dysfunction in diet-induced obesity. ( Berger, S; Lohmann, C; Lüscher, TF; Matter, CM; Miranda, MX; Nussberger, J; Ruschitzka, F; Schäfer, N; van Tits, LJ; Vergopoulos, A; Verrey, F; Winnik, S, 2013) |
| "Chronic inflammation in ankylosing spondylitis (AS) is associated with vascular endothelial dysfunction which leads to accelerated atherosclerosis." | 1.39 | Spironolactone improves endothelial dysfunction in ankylosing spondylitis. ( Garg, N; Kaur, L; Khichi, D; Syngle, A; Verma, I; Vohra, K, 2013) |
| "Spironolactone is an antifibrotic medication commonly used in heart failure to reduce mortality." | 1.38 | Spironolactone and colitis: increased mortality in rodents and in humans. ( Gillespie, BW; Govani, SM; Higgins, PD; Johnson, LA; Joyce, JC; Waljee, AK, 2012) |
| "In conclusion, in experimental hyperaldosteronism, the increase in CT-1 expression was associated with parameters showing LVH and fibrosis." | 1.37 | A role for cardiotrophin-1 in myocardial remodeling induced by aldosterone. ( Cachofeiro, V; Díez, J; Fortuno, MA; Lahera, V; López-Andrés, N; Martin-Fernandez, B; Rossignol, P; Zannad, F, 2011) |
| "Spironolactone treatment markedly suppressed osteopontin expression." | 1.35 | Spironolactone suppresses inflammation and prevents L-NAME-induced renal injury in rats. ( Hayashida, H; Hirakata, H; Iida, M; Ikeda, H; Masutani, K; Toyonaga, J; Tsuruya, K, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (5.45) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 10 (18.18) | 29.6817 |
| 2010's | 34 (61.82) | 24.3611 |
| 2020's | 8 (14.55) | 2.80 |
| Authors | Studies |
|---|---|
| Saunders, MJ | 1 |
| Edwards, BS | 1 |
| Zhu, J | 1 |
| Sklar, LA | 1 |
| Graves, SW | 1 |
| Kumar, N | 1 |
| Zuo, Y | 1 |
| Yalavarthi, S | 1 |
| Hunker, KL | 1 |
| Knight, JS | 1 |
| Kanthi, Y | 1 |
| Obi, AT | 1 |
| Ganesh, SK | 1 |
| Yamamoto, H | 1 |
| Yoshida, N | 1 |
| Kihara, S | 1 |
| Howard, ZM | 1 |
| Gomatam, CK | 1 |
| Rabolli, CP | 1 |
| Lowe, J | 1 |
| Piepho, AB | 1 |
| Bansal, SS | 1 |
| Accornero, F | 1 |
| Rafael-Fortney, JA | 1 |
| Areloegbe, SE | 2 |
| Peter, MU | 1 |
| Oyeleke, MB | 1 |
| Olaniyi, KS | 2 |
| Frątczak, A | 1 |
| Polak, K | 1 |
| Miziołek, B | 1 |
| Bergler-Czop, B | 1 |
| Areola, ED | 1 |
| Sabinari, IW | 1 |
| Fafure, AA | 1 |
| Agbana, RD | 1 |
| Atuma, CL | 1 |
| Shah, MZUH | 1 |
| Ajadi, IO | 1 |
| Olatunji, LA | 1 |
| Lin, M | 1 |
| Heizati, M | 1 |
| Wang, L | 1 |
| Nurula, M | 1 |
| Yang, Z | 1 |
| Wang, Z | 2 |
| Abudoyreyimu, R | 1 |
| Wu, Z | 1 |
| Li, N | 1 |
| Amer, RI | 1 |
| Yassin, GE | 1 |
| Mohamed, RA | 1 |
| Fayez, AM | 1 |
| Donderski, R | 1 |
| Stróżecki, P | 1 |
| Sulikowska, B | 1 |
| Grajewska, M | 1 |
| Miśkowiec, I | 1 |
| Stefańska, A | 1 |
| Siódmiak, J | 1 |
| Odrowąż-Sypniewska, G | 1 |
| Manitius, J | 1 |
| Barrera-Chimal, J | 1 |
| Rocha, L | 1 |
| Amador-Martínez, I | 1 |
| Pérez-Villalva, R | 1 |
| González, R | 1 |
| Cortés-González, C | 1 |
| Uribe, N | 1 |
| Ramírez, V | 1 |
| Berman, N | 1 |
| Gamba, G | 1 |
| Bobadilla, NA | 1 |
| Drzayich Antol, D | 1 |
| Waldman Casebeer, A | 1 |
| Khoury, R | 1 |
| Michael, T | 1 |
| Renda, A | 1 |
| Hopson, S | 1 |
| Parikh, A | 1 |
| Stein, A | 1 |
| Costantino, M | 1 |
| Stemkowski, S | 1 |
| Bunce, M | 1 |
| Nevo, N | 1 |
| Abu-Abeid, S | 1 |
| Hazzan, D | 1 |
| Lahat, G | 1 |
| Nachmani, I | 1 |
| Eldar, SM | 1 |
| Zhang, L | 1 |
| Xia, X | 1 |
| Zhong, Y | 1 |
| Xie, D | 1 |
| Liu, S | 1 |
| Wang, X | 2 |
| Tu, J | 1 |
| Faconti, L | 1 |
| Mills, CE | 1 |
| Govoni, V | 1 |
| Gu, H | 1 |
| Morant, S | 1 |
| Jiang, B | 1 |
| Cruickshank, JK | 1 |
| Webb, AJ | 1 |
| Lin, J | 1 |
| Wu, YJ | 1 |
| Liang, X | 1 |
| Ji, M | 1 |
| Ying, HM | 1 |
| Wang, XY | 1 |
| Sun, X | 1 |
| Shao, CH | 1 |
| Zhan, LX | 1 |
| Zhang, Y | 1 |
| Czamara, K | 1 |
| Karnas, E | 1 |
| Majka, Z | 1 |
| Wojcik, T | 1 |
| Zuba-Surma, EK | 1 |
| Baranska, M | 1 |
| Kaczor, A | 1 |
| Liu, X | 1 |
| Zhou, F | 1 |
| Yang, Y | 2 |
| Wang, W | 1 |
| Niu, L | 1 |
| Zuo, D | 1 |
| Li, X | 1 |
| Hua, H | 1 |
| Zhang, B | 1 |
| Kou, Y | 1 |
| Guo, J | 1 |
| Kong, F | 1 |
| Pan, W | 1 |
| Gao, D | 1 |
| Meves, JM | 1 |
| Sun, H | 1 |
| Xue, M | 1 |
| Zhang, Q | 1 |
| Wang, Y | 1 |
| Tang, R | 1 |
| Iso, T | 1 |
| Haruyama, H | 1 |
| Sunaga, H | 1 |
| Matsui, H | 1 |
| Matsui, M | 1 |
| Tanaka, R | 1 |
| Umbarawan, Y | 1 |
| Syamsunarno, MRAA | 1 |
| Putri, M | 1 |
| Yamaguchi, A | 1 |
| Hanaoka, H | 1 |
| Negishi, K | 1 |
| Yokoyama, T | 1 |
| Kurabayashi, M | 1 |
| Palomo-Briones, R | 1 |
| Esquivel-González, S | 1 |
| Aizpuru, A | 1 |
| Gómez-Hernández, N | 1 |
| Casas-Flores, S | 1 |
| Barba de la Rosa, AP | 1 |
| Arriaga, S | 1 |
| Peterson, ME | 1 |
| Carothers, MA | 1 |
| Gamble, DA | 1 |
| Rishniw, M | 1 |
| Liu, W | 1 |
| Gong, W | 1 |
| He, M | 1 |
| Liu, Y | 2 |
| Wang, M | 1 |
| Wu, M | 1 |
| Guo, S | 1 |
| Yu, Y | 1 |
| Sun, F | 2 |
| Li, Y | 1 |
| Zhou, L | 1 |
| Qin, S | 1 |
| Zhang, Z | 1 |
| Esposito, CT | 1 |
| Varahan, S | 1 |
| Jeyaraj, D | 1 |
| Lu, Y | 1 |
| Stambler, BS | 1 |
| Syngle, A | 1 |
| Vohra, K | 1 |
| Khichi, D | 1 |
| Garg, N | 1 |
| Verma, I | 1 |
| Kaur, L | 1 |
| Schäfer, N | 1 |
| Lohmann, C | 1 |
| Winnik, S | 1 |
| van Tits, LJ | 1 |
| Miranda, MX | 1 |
| Vergopoulos, A | 1 |
| Ruschitzka, F | 1 |
| Nussberger, J | 1 |
| Berger, S | 1 |
| Lüscher, TF | 1 |
| Verrey, F | 1 |
| Matter, CM | 1 |
| Dixit, S | 1 |
| Olsson, A | 1 |
| Fischer, G | 1 |
| Samanani, S | 1 |
| Mishra, M | 1 |
| Silva, C | 1 |
| Verhaeghe, B | 1 |
| Wang, J | 1 |
| Tong, J | 1 |
| Yong, VW | 1 |
| Saffouri, GB | 1 |
| Wittich, CM | 1 |
| Chen, H | 1 |
| Zhong, X | 1 |
| Shao, Y | 1 |
| Yoshimura, A | 1 |
| Armanini, D | 2 |
| Sabbadin, C | 2 |
| Donà, G | 1 |
| Clari, G | 1 |
| Bordin, L | 1 |
| Ye, L | 1 |
| Xie, W | 2 |
| Strong, JA | 2 |
| Zhang, JM | 2 |
| Ozacmak, HS | 1 |
| Ozacmak, VH | 1 |
| Barut, F | 1 |
| Araslı, M | 1 |
| Ucan, BH | 1 |
| Hofni, A | 1 |
| El-Moselhy, MA | 1 |
| Taye, A | 1 |
| Khalifa, MM | 1 |
| DeMarco, VG | 1 |
| Habibi, J | 1 |
| Jia, G | 1 |
| Aroor, AR | 1 |
| Ramirez-Perez, FI | 1 |
| Martinez-Lemus, LA | 1 |
| Bender, SB | 1 |
| Garro, M | 1 |
| Hayden, MR | 1 |
| Sun, Z | 1 |
| Meininger, GA | 1 |
| Manrique, C | 1 |
| Whaley-Connell, A | 1 |
| Sowers, JR | 1 |
| Wang, S | 1 |
| Li, B | 1 |
| Li, C | 1 |
| Cui, W | 1 |
| Miao, L | 1 |
| Martín-Fernández, B | 3 |
| Rubio-Navarro, A | 1 |
| Cortegano, I | 1 |
| Ballesteros, S | 2 |
| Alía, M | 1 |
| Cannata-Ortiz, P | 1 |
| Olivares-Álvaro, E | 1 |
| Egido, J | 1 |
| de Andrés, B | 1 |
| Gaspar, ML | 1 |
| de Las Heras, N | 2 |
| Lahera, V | 3 |
| Moreno, JA | 1 |
| Calò, LA | 1 |
| Dinh, QN | 1 |
| Young, MJ | 1 |
| Evans, MA | 1 |
| Drummond, GR | 1 |
| Sobey, CG | 1 |
| Chrissobolis, S | 1 |
| Busby, J | 1 |
| Murchie, P | 1 |
| Murray, L | 1 |
| Iversen, L | 1 |
| Lee, AJ | 1 |
| Spence, A | 1 |
| Watson, MC | 1 |
| Cardwell, CR | 1 |
| Ikeda, H | 1 |
| Tsuruya, K | 1 |
| Toyonaga, J | 1 |
| Masutani, K | 1 |
| Hayashida, H | 1 |
| Hirakata, H | 1 |
| Iida, M | 1 |
| Yamanari, H | 1 |
| Nakamura, K | 1 |
| Miura, D | 1 |
| Yamanari, S | 1 |
| Ohe, T | 1 |
| Wada, T | 1 |
| Kenmochi, H | 1 |
| Miyashita, Y | 1 |
| Sasaki, M | 1 |
| Ojima, M | 1 |
| Sasahara, M | 1 |
| Koya, D | 1 |
| Tsuneki, H | 1 |
| Sasaoka, T | 1 |
| Tirosh, A | 1 |
| Garg, R | 1 |
| Adler, GK | 1 |
| Deuchar, GA | 1 |
| McLean, D | 1 |
| Hadoke, PWF | 1 |
| Brownstein, DG | 1 |
| Webb, DJ | 1 |
| Mullins, JJ | 1 |
| Chapman, K | 1 |
| Seckl, JR | 1 |
| Kotelevtsev, YV | 1 |
| Irita, J | 1 |
| Okura, T | 1 |
| Jotoku, M | 1 |
| Nagao, T | 1 |
| Enomoto, D | 1 |
| Kurata, M | 1 |
| Desilva, VR | 1 |
| Miyoshi, K | 1 |
| Matsui, Y | 1 |
| Uede, T | 1 |
| Denhardt, DT | 1 |
| Rittiling, SR | 1 |
| Higaki, J | 2 |
| López-Andrés, N | 1 |
| Rossignol, P | 1 |
| Zannad, F | 1 |
| Fortuno, MA | 1 |
| Cachofeiro, V | 2 |
| Díez, J | 1 |
| Brandt, CJ | 1 |
| Kammer, D | 1 |
| Fiebeler, A | 1 |
| Klinge, U | 1 |
| Johnson, LA | 1 |
| Govani, SM | 1 |
| Joyce, JC | 1 |
| Waljee, AK | 1 |
| Gillespie, BW | 1 |
| Higgins, PD | 1 |
| Miana, M | 1 |
| Valero-Muñoz, M | 1 |
| Vassallo, D | 1 |
| Davel, AP | 1 |
| Rossoni, LV | 1 |
| Luther, JM | 1 |
| Luo, P | 1 |
| Cohen, SE | 1 |
| Kim, HS | 1 |
| Fogo, AB | 1 |
| Brown, NJ | 1 |
| Dong, F | 1 |
| Nielsen, SE | 1 |
| Schjoedt, KJ | 1 |
| Rossing, K | 1 |
| Persson, F | 1 |
| Schalkwijk, CG | 1 |
| Stehouwer, CD | 1 |
| Parving, HH | 1 |
| Rossing, P | 1 |
| Raz-Pasteur, A | 1 |
| Gamliel-Lazarovich, A | 1 |
| Gantman, A | 1 |
| Coleman, R | 1 |
| Keidar, S | 1 |
| Sun, Y | 2 |
| Zhang, J | 1 |
| Lu, L | 1 |
| Chen, SS | 1 |
| Quinn, MT | 1 |
| Weber, KT | 2 |
| Funder, JW | 2 |
| BAJUSZ, E | 1 |
| JASMIN, G | 1 |
| HIEMEYER, V | 1 |
| KAEHLER, HJ | 1 |
| Hansen, PR | 1 |
| Rieneck, K | 1 |
| Bendtzen, K | 1 |
| Meier, DJ | 1 |
| Pitt, B | 1 |
| Rajagopalan, S | 1 |
| Chhokar, VS | 1 |
| Bhattacharya, SK | 1 |
| Ahokas, RA | 1 |
| Myers, LK | 1 |
| Xing, Z | 1 |
| Smith, RA | 1 |
| Gerling, IC | 1 |
| Bhatia, V | 1 |
| Suzuki, J | 1 |
| Iwai, M | 1 |
| Mogi, M | 1 |
| Oshita, A | 1 |
| Yoshii, T | 1 |
| Horiuchi, M | 1 |
| Selye, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Mineralocorticoid Receptor, Coronary Microvascular Function, and Cardiac Efficiency in Hypertension[NCT05593055] | Phase 4 | 75 participants (Anticipated) | Interventional | 2023-08-25 | Recruiting | ||
| Pilot Randomized Controlled Trial of Spironolactone in Young Women With Nonalcoholic Steatohepatitis (NASH)[NCT03576755] | Phase 1/Phase 2 | 20 participants (Actual) | Interventional | 2019-01-09 | Completed | ||
| Cardiometabolic Effects of Eplerenone in HIV Infection[NCT02629094] | Phase 2 | 5 participants (Actual) | Interventional | 2015-12-02 | Terminated | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Mean change in intraventricular septum percentage of lipid by MR spectroscopy. This was calculated by subtracting the baseline intraventicular septum percentage value of lipid from the week 24 intraventicular septum percentage value of lipid by MR spectroscopy. (NCT02629094)
Timeframe: 24 weeks
| Intervention | percentage of lipid (Mean) |
|---|---|
| Eplerenone | -0.33 |
Mean change in hepatic percentage of lipid by MR spectroscopy. This was calculated by subtracting the baseline hepatic percentage value of lipid from the week 24 hepatic percentage value of lipid by MR spectroscopy. (NCT02629094)
Timeframe: 24 weeks
| Intervention | percentage of lipid (Mean) |
|---|---|
| Eplerenone | 13 |
6 reviews available for spironolactone and Inflammation
| Article | Year |
|---|---|
A systematic review and meta-analysis of effects of spironolactone on blood pressure, glucose, lipids, renal function, fibrosis and inflammation in patients with hypertension and diabetes.
Topics: Blood Glucose; Blood Pressure; Diabetes Complications; Humans; Hypertension; Inflammation; Kidney; K | 2021 |
Potential Renoprotective Agents through Inhibiting CTGF/CCN2 in Diabetic Nephropathy.
Topics: Animals; Anthocyanins; Antibodies, Monoclonal; Connective Tissue Growth Factor; Diabetes Mellitus; D | 2015 |
Mineralocorticoid receptor antagonists and the metabolic syndrome.
Topics: Aldosterone; Antihypertensive Agents; Eplerenone; Humans; Hypertension; Inflammation; Insulin Resist | 2010 |
Aldosterone resurgens--letter from EPHESUS.
Topics: Aldosterone; Animals; Cardiac Output, Low; Cardiovascular Diseases; Eplerenone; Humans; Inflammation | 2003 |
Eplerenone: will it have a role in the treatment of acute coronary syndromes?
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Collagen; Coronary Restenosis; Eplerenone; Humans; | 2004 |
Insulin resistance in polycystic ovarian disease.
Topics: Cardiovascular Diseases; Female; Follicle Stimulating Hormone; Humans; Hypoglycemic Agents; Inflamma | 2005 |
4 trials available for spironolactone and Inflammation
| Article | Year |
|---|---|
Topics: Adult; Aged; Animals; Astrocytes; Bariatric Surgery; Beta vulgaris; Bioreactors; Biotechnology; Bloo | 2018 |
Spironolactone and chlorthalidone in uncontrolled elderly hypertensive patients treated with calcium antagonists and angiotensin II receptor-blocker: effects on endothelial function, inflammation, and oxidative stress.
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pre | 2009 |
Levels of NT-proBNP, markers of low-grade inflammation, and endothelial dysfunction during spironolactone treatment in patients with diabetic kidney disease.
Topics: Albuminuria; Biomarkers; Diabetes Mellitus, Type 1; Diabetic Nephropathies; Double-Blind Method; End | 2013 |
RALES, EPHESUS and redox.
Topics: Aldosterone; Animals; Heart Failure; Humans; Inflammation; Mineralocorticoid Receptor Antagonists; M | 2005 |
45 other studies available for spironolactone and Inflammation
| Article | Year |
|---|---|
Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
Topics: Animals; Biotinylation; Flow Cytometry; Fluorescence Resonance Energy Transfer; Green Fluorescent Pr | 2010 |
SARS-CoV-2 Spike Protein S1-Mediated Endothelial Injury and Pro-Inflammatory State Is Amplified by Dihydrotestosterone and Prevented by Mineralocorticoid Antagonism.
Topics: Angiotensin Receptor Antagonists; Cell Adhesion Molecules; Cells, Cultured; COVID-19; Dihydrotestost | 2021 |
Esaxerenone Blocks Vascular Endothelial Inflammation Through SGK1.
Topics: Anti-Inflammatory Agents; Cytokines; Endothelial Cells; Glucocorticoids; Humans; Inflammation; NF-ka | 2022 |
Mineralocorticoid receptor antagonists and glucocorticoids differentially affect skeletal muscle inflammation and pathology in muscular dystrophy.
Topics: Animals; Cytokines; Fibronectins; Glucocorticoids; Inflammation; Mice; Mice, Inbred mdx; Mineralocor | 2022 |
Low-dose spironolactone ameliorates adipose tissue inflammation and apoptosis in letrozole-induced PCOS rat model.
Topics: Adipose Tissue; Animals; Apoptosis; Female; Humans; Inflammation; Letrozole; Polycystic Ovary Syndro | 2022 |
Torasemide-induced Vascular Purpura in the Course of Eosinophilic Granulomatosis with Polyangiitis.
Topics: Adolescent; Aged; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Antinuclear; Antihypertensive | 2022 |
Low-dose spironolactone combats dyslipidemia and hepatic inflammation by modulating PCSK9 in rat model of polycystic ovarian syndrome.
Topics: Animals; Dyslipidemias; Female; Humans; Inflammation; Letrozole; NLR Family, Pyrin Domain-Containing | 2023 |
Pharmaceutical and Pharmacological Evaluation of the Effect of Nano-Formulated Spironolactone and Progesterone on Inflammation and Hormonal Levels for Managing Hirsutism Experimentally Induced in Rats.
Topics: Animals; Drug Carriers; Drug Evaluation, Preclinical; Female; Hirsutism; Hydrogels; Inflammation; Na | 2021 |
Aldosterone antagonist therapy and its relationship with inflammation, fibrosis, thrombosis, mineral-bone disorder and cardiovascular complications in peritoneal dialysis (PD) patients.
Topics: Adult; Aged; Aged, 80 and over; Aldosterone; Biomarkers; Blood Pressure; Cardiovascular Diseases; Ch | 2017 |
Delayed spironolactone administration prevents the transition from acute kidney injury to chronic kidney disease through improving renal inflammation.
Topics: Acute Kidney Injury; Animals; Delayed-Action Preparations; Disease Models, Animal; Disease Progressi | 2019 |
Spironolactone Protects against Diabetic Cardiomyopathy in Streptozotocin-Induced Diabetic Rats.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetic Cardiomyopathies; Inflammation; Male; Myocardium; | 2018 |
Spironolactone improves the arrhythmogenic substrate in heart failure by preventing ventricular electrical activation delays associated with myocardial interstitial fibrosis and inflammation.
Topics: Animals; Arrhythmias, Cardiac; Dogs; Electrophysiological Phenomena; Fibrosis; Heart Failure; Heart | 2013 |
Spironolactone improves endothelial dysfunction in ankylosing spondylitis.
Topics: Adolescent; Adult; Atherosclerosis; Blood Sedimentation; Brachial Artery; C-Reactive Protein; Diuret | 2013 |
Endothelial mineralocorticoid receptor activation mediates endothelial dysfunction in diet-induced obesity.
Topics: Adipose Tissue; Aldosterone; Animals; Antioxidants; Aorta; Cyclooxygenase 1; Cyclooxygenase Inhibito | 2013 |
A case series of 11 patients with hormone-responsive sebaceous adenitis of the labia minora.
Topics: Adolescent; Adult; Androgen Antagonists; Anti-Bacterial Agents; Cyproterone Acetate; Drug Combinatio | 2014 |
Screening for inhibitors of microglia to reduce neuroinflammation.
Topics: Cells, Cultured; Drug Evaluation, Preclinical; Fetus; Humans; Inflammation; Lipopolysaccharides; Mic | 2013 |
83-year-old man with abdominal swelling and lower extremity edema.
Topics: Abdominal Cavity; Aged, 80 and over; Anti-Infective Agents; Ascites; Cefotaxime; Diagnosis, Differen | 2013 |
Eplerenone-mediated aldosterone blockade prevents renal fibrosis by reducing renal inflammation, interstitial cell proliferation and oxidative stress.
Topics: Animals; Cell Proliferation; Disease Models, Animal; Eplerenone; Fibrosis; Inflammation; Male; Miner | 2013 |
Aldosterone receptor blockers spironolactone and canrenone: two multivalent drugs.
Topics: Albuminuria; Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Canrenone; Humans; Hypertension; | 2014 |
Blocking the mineralocorticoid receptor improves effectiveness of steroid treatment for low back pain in rats.
Topics: Androstadienes; Animals; Disease Models, Animal; Eplerenone; Fluticasone; Ganglia, Spinal; Inflammat | 2014 |
Pretreatment with mineralocorticoid receptor blocker reduces intestinal injury induced by ischemia and reperfusion: involvement of inhibition of inflammatory response, oxidative stress, nuclear factor κB, and inducible nitric oxide synthase.
Topics: Animals; Glutathione; Inflammation; Male; Mineralocorticoid Receptor Antagonists; Neutrophil Infiltr | 2014 |
Combination therapy with spironolactone and candesartan protects against streptozotocin-induced diabetic nephropathy in rats.
Topics: Animals; Antioxidants; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Cyclooxygenase 2; Diabete | 2014 |
Low-Dose Mineralocorticoid Receptor Blockade Prevents Western Diet-Induced Arterial Stiffening in Female Mice.
Topics: Animals; Aorta; Arteriosclerosis; Diet, Western; Dose-Response Relationship, Drug; Endothelial Cells | 2015 |
Aldosterone Induces Renal Fibrosis and Inflammatory M1-Macrophage Subtype via Mineralocorticoid Receptor in Rats.
Topics: Aldosterone; Animals; Fibrosis; Inflammation; Kidney; Kidney Diseases; Macrophages; Male; Mineraloco | 2016 |
The story of spironolactones from 1957 to now: from sodium balance to inflammation.
Topics: Aldosterone; History, 20th Century; History, 21st Century; Hypertension; Inflammation; Mineralocorti | 2016 |
Aldosterone-induced oxidative stress and inflammation in the brain are mediated by the endothelial cell mineralocorticoid receptor.
Topics: Aldosterone; Animals; Blood Pressure; Brain; Cerebrovascular Circulation; Cytokines; Endothelial Cel | 2016 |
The effect of medications which cause inflammation of the gastro-oesophageal tract on cancer risk: a nested case-control study of routine Scottish data.
Topics: Adult; Aged; Aged, 80 and over; Diphosphonates; Esophageal Neoplasms; Female; Humans; Inflammation; | 2017 |
Spironolactone suppresses inflammation and prevents L-NAME-induced renal injury in rats.
Topics: Animals; Fibrosis; Hemodynamics; Inflammation; Kidney Diseases; Male; NG-Nitroarginine Methyl Ester; | 2009 |
Spironolactone improves glucose and lipid metabolism by ameliorating hepatic steatosis and inflammation and suppressing enhanced gluconeogenesis induced by high-fat and high-fructose diet.
Topics: Animals; Body Weight; Cells, Cultured; Dietary Carbohydrates; Dietary Fats; Fatty Liver; Gene Expres | 2010 |
11β-hydroxysteroid dehydrogenase type 2 deficiency accelerates atherogenesis and causes proinflammatory changes in the endothelium in apoe-/- mice.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 2; Amiloride; Animals; Aorta; Apolipoproteins E; Atheroscl | 2011 |
Osteopontin deficiency protects against aldosterone-induced inflammation, oxidative stress, and interstitial fibrosis in the kidney.
Topics: Albuminuria; Aldosterone; Animals; Blood Pressure; Eplerenone; Fibrosis; Inflammation; Kidney; Male; | 2011 |
A role for cardiotrophin-1 in myocardial remodeling induced by aldosterone.
Topics: Aldosterone; Animals; Blood Pressure; Blotting, Western; Collagen; Cytokines; Disease Models, Animal | 2011 |
Beneficial effects of hydrocortisone or spironolactone coating on foreign body response to mesh biomaterial in a mouse model.
Topics: Animals; Coated Materials, Biocompatible; Collagen; Disease Models, Animal; Foreign-Body Reaction; G | 2011 |
Spironolactone and colitis: increased mortality in rodents and in humans.
Topics: Animals; Clostridioides difficile; Clostridium Infections; Colitis; Crohn Disease; Female; Fibrosis; | 2012 |
Spironolactone prevents alterations associated with cardiac hypertrophy produced by isoproterenol in rats: involvement of serum- and glucocorticoid-regulated kinase type 1.
Topics: Aldosterone; Animals; Blood Pressure; Cardiomegaly; Fibrosis; Heart; Immediate-Early Proteins; Infla | 2012 |
Aldosterone deficiency and mineralocorticoid receptor antagonism prevent angiotensin II-induced cardiac, renal, and vascular injury.
Topics: Aldosterone; Angiotensin II; Animals; Aorta; Biomarkers; Blood Pressure; Cytochrome P-450 CYP11B2; D | 2012 |
Mineralocorticoid receptor blocker eplerenone reduces pain behaviors in vivo and decreases excitability in small-diameter sensory neurons from local inflamed dorsal root ganglia in vitro.
Topics: Animals; Behavior, Animal; Eplerenone; Ganglia, Spinal; Inflammation; Male; Mineralocorticoid Recept | 2012 |
Mineralocorticoid receptor blockade inhibits accelerated atherosclerosis induced by a low sodium diet in apolipoprotein E-deficient mice.
Topics: Aldosterone; Animals; Aorta; Apolipoproteins E; Atherosclerosis; Biomarkers; Diet, Sodium-Restricted | 2014 |
Aldosterone-induced inflammation in the rat heart : role of oxidative stress.
Topics: Aldosterone; Animals; Antioxidants; Cardiomyopathies; Cell Division; Cell Movement; Fibrosis; Heart; | 2002 |
Effect of aldactone, an antiminera-locorticoid steroid spironolactone, on inflammation.
Topics: Aldosterone; Diuretics; Hydrocortisone; Inflammation; Mineralocorticoid Receptor Antagonists; Spiron | 1961 |
[The antiphlogistic effect and mechanism of action of spironolactone].
Topics: Aldosterone; Diuretics; Inflammation; Mineralocorticoid Receptor Antagonists; Spironolactone | 1962 |
Spironolactone inhibits production of proinflammatory cytokines by human mononuclear cells.
Topics: Aldosterone; Canrenoic Acid; Cells, Cultured; Cyproterone Acetate; Cytokines; Enzyme-Linked Immunoso | 2004 |
Hyperparathyroidism and the calcium paradox of aldosteronism.
Topics: Aldosterone; Animals; Bone Density; Bone Resorption; Calcium; Hyperaldosteronism; Hyperparathyroidis | 2005 |
Eplerenone with valsartan effectively reduces atherosclerotic lesion by attenuation of oxidative stress and inflammation.
Topics: Aldosterone; Animals; Aorta; Atherosclerosis; Blood Pressure; Cells, Cultured; Chemokine CCL2; Chole | 2006 |
The Harry G. Armstrong Lecture. Stress and aerospace medicine.
Topics: Adaptation, Biological; Adrenal Glands; Aerospace Medicine; Ethylestrenol; Glucocorticoids; Growth H | 1973 |